When was Corline Biomedical founded?

Corline Biomedical was founded in 1991 and raised its 1st funding round 20 years after it was founded.

Where is Corline Biomedical located?

Corline Biomedical is headquartered in Uppsala, Sweden.

Who is the current CEO of Corline Biomedical?

Henrik Nittmar of Corline Biomedical.

How many employees does Corline Biomedical have?

As of Aug 31, 2026, the latest employee count at Corline Biomedical is 20.

Is Corline Biomedical a funded company?

Corline Biomedical is a funded company, having raised an undisclosed amount across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jun 07, 2011.

When was the latest funding round of Corline Biomedical?

Corline Biomedical's latest funding was a $***** Post IPO round on Mar 29, 2021, with participation from 2 investors.

Where does Corline Biomedical rank among its competitors?

Corline Biomedical ranks 16th amongst 112 active competitors, of which 38 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Regenfro Co, which secured $7.56M in Jun, 2026.

Who are the top competitors of Corline Biomedical?

Corline Biomedical's top competitors include Akebia Therapeutics, Aurinia Pharmaceuticals and Alebund. Among them, Regenfro Co secured the most recent funding round in June, 2026.

Corline Biomedical - 2026 Company Profile, Team, Funding & Competitors

Corline Biomedical is a public company based in Uppsala (Sweden), founded in 1991. It operates as a Developing solutions for transplantation, implants and regenerative medicine using a proprietary heparin platform. Corline Biomedical has raised an undisclosed amount in funding. The company has 112 active competitors, including 38 funded and 30 that have exited. Its top competitors include companies like Akebia Therapeutics, Aurinia Pharmaceuticals and Alebund.

Company Details

Corline Biomedical is a public company that develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. The company's products are based on its proprietary Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as a stand-alone pharmaceutical compound; and Corline Heparin Surface (CHS), a surface coating that is used in conventional medical devices for blood compatibility. The company’s products include Renaparin for use in the treatment of end-stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries. It also provides heparin coating kits, which allows the customers to coat one-off items and equipment in a lab setting; and CHS coronary stents, a metallic tube-shaped device, which is placed in the coronary arteries that supplies blood to the heart, for the treatment of acute or threatened vessel closure during coronary angioplasty.

Website: www.corline.se/
Email ID: *****@corline.se

Key Metrics

Founded Year

1991

Location

Uppsala, Sweden

Stage

Public

Latest Funding Round

Post IPO, Mar 29, 2021, $*****

Investors

EIC Fund & 3 more

Ranked

16^th among 112 active competitors

Employee Count

20 as on Aug 31, 2026

Similar Companies

Akebia Therapeutics & 125 more

Exit Details

Public

View Corline Biomedical's full profile

Corline Biomedical got listed on Jun 05, 2015.

Click here to take a look at Corline Biomedical's IPO in detail

Corline Biomedical has raised funding over 6 rounds. Its first funding round was on Jun 07, 2011. Its latest funding round was a Post IPO round on Mar 29, 2021 for $*****. 2 investors participated in its latest round. Corline Biomedical has 4 institutional investors.

Here is the list of recent funding rounds of Corline Biomedical:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 29, 2021	2933760	Post IPO	9681372	3921009	2931483	4337092
Feb 28, 2019	7111393	Grant (prize money)	2709340	4653593	8063837	EIC Fund
Mar 01, 2017	1448403	Grant (prize money)	9934718	3452121	3273092	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Corline Biomedical's funding rounds and investors

Corline Biomedical's employee count trend

Corline Biomedical has 20 employees as of Aug 26. Here is Corline Biomedical's employee count trend over the years:

Employee count trend for Corline Biomedical

Uncover Corline Biomedical's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Corline Biomedical include Akebia Therapeutics, Aurinia Pharmaceuticals and Alebund. Here is the list of Top 10 competitors of Corline Biomedical, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Akebia Therapeutics 2007, Cincinnati (United States), Public	Developing therapeutics solutions to treat patients with kidney disease	$91M	Genechem, Longitude Capital & 13 others	65/100
2nd	Aurinia Pharmaceuticals 1993, Edmonton (Canada), Public	Developer of therapeutics for autoimmune diseases	-	RA Capital Management, VenBio & 10 others	64/100
3rd	Alebund 2018, Shanghai (China), Public	Developer of therapeutics for kidney diseases	$114M	Morningside, Loayal Valley Capital & 14 others	63/100
4th	Enyo Pharma 2014, Lyon (France), Series C	Developer of therapeutics for diseases with impaired kidney function	$120M	Orbimed, Morningside & 9 others	62/100
5th	Renalys 2023, Chuo City (Japan), Acquired	Developer of therapeutics for the treatment of renal diseases	$38.2M	SR One, Catalys Pacific & 4 others	61/100
6th	Arthrosi Therapeutics 2017, Irvine (United States), Acquired	Developer of therapeutics for gout, chronic kidney diseases, and oncology	$293M	Prime Eight Capital, Guangrun Health Industry ... & 11 others	61/100
7th	Secretome Therapeutics 2018, Dallas (United States), Series A	Developer of cell-based therapies for multiple diseases	$52.2M	RA Capital Management, Parent Project Muscular Dystrophy ... & 2 others	60/100
8th	Calliditas Therapeutics 2004, Stockholm (Sweden), Public	Provider of small molecule based drug for inflammatory kidney disease	$44.8M	Investinor, Athyrium Capital Management & 3 others	58/100
9th	Purespring Therapeutics 2020, London (United Kingdom), Series B	Developer of therapeutics for chronic renal diseases	$164M	Syncona, Sofinnova Partners & 3 others	56/100
10th	Regenfro Co 2019, Kyoto (Japan), Series B	Developer of therapeutics to treat renal diseases	$36.4M	Mitsubishi UFJ Capital, Kyoto University Innovation Capital ... & 24 others	56/100
16th	Corline Biomedical 1991, Uppsala (Sweden), Public	Developing solutions for transplantation, implants and regenerative medicine using a proprietary heparin platform	-	EIC Fund, M2 Asset Management AB & 2 others	52/100